65934-74-9 Usage
Description
4-Methyl-3-(trifluoromethyl)aniline is an organic compound that features a methyl group at the 4-position and a trifluoromethyl group at the 3-position attached to an aniline core. It is characterized by its colorless to light brown crystalline appearance.
Uses
Used in Pharmaceutical Synthesis:
4-Methyl-3-(trifluoromethyl)aniline is used as a starting reagent for the synthesis of tert-butyl 4-methyl-3-(trifluoromethyl)phenylcarbamate, which is a compound of interest in the pharmaceutical industry. Its unique structure and properties make it a valuable precursor in the development of new drugs and therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 65934-74-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,5,9,3 and 4 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 65934-74:
(7*6)+(6*5)+(5*9)+(4*3)+(3*4)+(2*7)+(1*4)=159
159 % 10 = 9
So 65934-74-9 is a valid CAS Registry Number.
InChI:InChI=1/C6H10F4O/c1-5(2,3)11-6(9,10)4(7)8/h4H,1-3H3
65934-74-9Relevant articles and documents
Substituted diaryl amide compound as well as preparation method and application thereof
-
Paragraph 0205; 0216; 0217, (2019/04/04)
The invention provides a substituted diaryl amide compound as well as a preparation method and application thereof. The substituted diaryl amide compound or a pharmaceutically acceptable salt thereofis of a structure of a formula [1] (the formula is shown
HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
-
, (2010/11/28)
The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.